➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
AstraZeneca
Baxter
Moodys
Mallinckrodt

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TELAVANCIN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Telavancin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00061633 ↗ Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2003-06-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
NCT00062647 ↗ Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2003-08-01 The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
NCT00077675 ↗ Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed Theravance Biopharma Antibiotics, Inc. Phase 2 2004-02-01 Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
NCT00091819 ↗ Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Completed Theravance Biopharma Antibiotics, Inc. Phase 3 2005-01-01 Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
NCT00107952 ↗ Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed Theravance Biopharma Antibiotics, Inc. Phase 3 2005-02-01 Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
NCT00107978 ↗ Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Completed Theravance Biopharma Antibiotics, Inc. Phase 3 2005-02-01 Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
NCT00124020 ↗ Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed Theravance Biopharma Antibiotics, Inc. Phase 3 2005-01-01 Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Telavancin Hydrochloride

Condition Name

Condition Name for Telavancin Hydrochloride
Intervention Trials
Bacteremia 2
Infections, Gram-Positive Bacterial 2
Staphylococcal Skin Infection 2
Bacterial Pneumonia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Telavancin Hydrochloride
Intervention Trials
Communicable Diseases 5
Infection 5
Gram-Positive Bacterial Infections 4
Staphylococcal Infections 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Telavancin Hydrochloride

Trials by Country

Trials by Country for Telavancin Hydrochloride
Location Trials
United States 18
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Telavancin Hydrochloride
Location Trials
California 4
Ohio 2
Minnesota 1
Florida 1
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Telavancin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Telavancin Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Telavancin Hydrochloride
Clinical Trial Phase Trials
Completed 11
Recruiting 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Telavancin Hydrochloride

Sponsor Name

Sponsor Name for Telavancin Hydrochloride
Sponsor Trials
Theravance Biopharma Antibiotics, Inc. 14
M.D. Anderson Cancer Center 1
Joseph Kuti 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Telavancin Hydrochloride
Sponsor Trials
Industry 15
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
Mallinckrodt
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.